Bayer AG - ADR

This is a pivotal committee for Bayer, as it controls tax policy (corporate valuations), trade policy (tariffs impacting global supply chains), and entitlement spending (Medicare drug pricing), all of which directly impact profitability and market access.

This committee allocates federal discretionary spending, directly determining the budgets of key regulatory agencies (FDA, EPA, NIH) and major customers (VA, DoD), which profoundly affects Bayer's operating environment and sales.

This committee's jurisdiction over the Farm Bill and agricultural policy directly impacts Bayer's Crop Science segment, including regulations for seeds, crop protection, and agricultural practices in the US.

This committee directly oversees the FDA, which regulates Bayer's pharmaceutical and consumer health products. It also influences NIH research funding and labor laws, all profoundly impacting Bayer's operations and R&D.

This committee's oversight of antitrust laws and intellectual property is critically important to Bayer. It influences mega-mergers (like the Monsanto acquisition), protects pharmaceutical and seed patents, and can initiate antitrust actions.

Although advisory, this committee's investigations into issues like drug pricing and long-term care for older Americans create significant 'headline risk' and influence public and policy discussions directly affecting Bayer's Pharmaceutical segment.

This committee oversees the Department of Veterans Affairs, a major purchaser of healthcare products. Its funding decisions directly impact demand for Bayer's pharmaceutical and diagnostic imaging products used by veterans.

This committee directly regulates the EPA, which has significant oversight over Bayer's Crop Science segment (pesticides, herbicides, seeds) and its chemical manufacturing processes, directly impacting compliance costs and product approvals.